Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma

Phase 2 Completed 80 enrolled The Lymphoma Academic Research Organisation Centre Henri Becquerel · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and Prednisone) in a population of patients with follicular lymphoma as measured by the response rate at the end of treatment.

Timeline

Start: 2010-12
Primary completion: 2013-07
Completion: 2015-11

Publications

Tilly H, Morschhauser F, Casasnovas O, Molina TJ, Feugier P, Gouill SL, Haioun C, Tournilhac O, Bouabdallah R, Gabarre J, Lamy T, Cabecadas J, Becker S, Jardin F, Mounier N, Salles G; Lymphoma Study Association. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. Lancet Haematol. 2018 Sep;5(9):e403-e410. doi: 10.1016/S2352-3026(18)30131-5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lenalidomide	Other / unclassified	25 mg	Oral
Background	Cyclophosphamide	Other / unclassified	—	—
Background	Doxorubicin	Other / unclassified	—	—
Background	Prednisone	Other / unclassified	—	—
Background	Rituximab	Monoclonal antibody	—	—
Background	Vincristine	Small molecule	—	—

Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma

Summary

Timeline

Publications

Drugs

Indications